Log In
Print this Print this

Oral antiTNF, pr-antiTNF (OPRX-106) (formerly PRX-106)

  Manage Alerts
Collapse Summary General Information
Company Protalix BioTherapeutics Inc.
DescriptionPlant cell-expressed recombinant TNF receptor 2 (TNFR2) fused to an IgG1 Fc domain
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor
Therapeutic ModalityBiologic: Fusion protein

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today